WASHINGTON -- A Georgetown University professor published in the online journal PLOS ONE the first study explaining why drugs designed to fight off malaria stop working in some people with the disease.
Malaria, a mosquito-borne disease caused by a parasite, killed more than 650,000 people in 2010 - most of them children in Africa, according to the World Health Organization.
While several antimalarial drugs have successfully treated the disease, in some regions they no longer work due to drug resistance. Given that just last month the CDC reported that malaria cases in the U.S. reached a 40-year high, this research is particularly timely.
A Global Threat
"Resistance to antimalarial medication threatens the health of more than half of the world's population," notes corresponding Paul Roepe, PhD, a Georgetown chemistry professor who authored the study with colleagues at the University of Notre Dame and the University of Kentucky.
Many antimalarial drugs both slow the growth of malarial parasites, and, at higher doses or over longer periods of time, also kill the malarial parasites.
"Until now, no studies have separated how resistance to these two different drug actions might work," says Roepe, also a professor of biochemistry and cell and molecular biology and co-founder of Georgetown's Center for Infectious Disease at Georgetown University Medical Center. "Our study found genetic and cell biological evidence linking autophagy to resistance to the parasite, which kills the effects of drugs."
Autophagy, Roepe explains, is the process by which cells remove damaged parts of themselves to restore normal function. In this case, the cell rids itself of the parts damaged by the antimalarial drug. Roepe worked with two alumni of the chemistry Ph.D. program, David Gaviria (G'13) and Michelle Paguio (G'09), as well as current student Ph.D. chemistry student Amila Siriwardana (G'16) on the research.
The professor and his colleagues demonstrated in their study that while resistance to drugs like chloroquine, which works to slow the growth of malaria, has been explored, an explanation of the resistance to the cell-destroying effects of the medication has not been fully understood.
"These results have important implications in the ongoing development of new antimalarial drug therapy," Roepe says. "We hope that by publishing this work in an open access journal, more researchers will access it and can expedite drug development.
This research was supported by grants from the National Institutes of Health (RO1 AI045957, RO1AI49367, RO1 AI071121) and by a Kentucky Science and Engineering Foundation award. The authors declare no conflict of interest.
About Georgetown University
Established in 1789, Georgetown is the nation's oldest Catholic and Jesuit university. Drawing upon this legacy, we provide students with a world-class learning experience focused on educating the whole person through exposure to different faiths, cultures and beliefs. With our Jesuit values and location in Washington, D.C., Georgetown offers students a distinct opportunity to learn, experience and understand more about the world.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.